Browse PPIB

Summary
SymbolPPIB
Namepeptidylprolyl isomerase B (cyclophilin B)
Aliases CYPB; OI9; CYP-S1; HEL-S-39; SCYLP; PPIase B; S-cyclophilin; cyclophilin-like protein; epididymis secretory ......
Chromosomal Location15q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum lumen Melanosome Note=Identified by mass spectrometry in melanosome fractions from stage I to stage IV (PubMed:17081065).
Domain PF00160 Cyclophilin type peptidyl-prolyl cis-trans isomerase/CLD
Function

PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides.

> Gene Ontology
 
Biological Process GO:0000413 protein peptidyl-prolyl isomerization
GO:0001501 skeletal system development
GO:0006457 protein folding
GO:0018208 peptidyl-proline modification
GO:0019058 viral life cycle
GO:0019079 viral genome replication
GO:0031647 regulation of protein stability
GO:0035264 multicellular organism growth
GO:0035821 modification of morphology or physiology of other organism
GO:0040014 regulation of multicellular organism growth
GO:0040018 positive regulation of multicellular organism growth
GO:0043900 regulation of multi-organism process
GO:0043902 positive regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0044788 modulation by host of viral process
GO:0044794 positive regulation by host of viral process
GO:0044827 modulation by host of viral genome replication
GO:0044829 positive regulation by host of viral genome replication
GO:0045069 regulation of viral genome replication
GO:0045070 positive regulation of viral genome replication
GO:0045927 positive regulation of growth
GO:0048524 positive regulation of viral process
GO:0048638 regulation of developmental growth
GO:0048639 positive regulation of developmental growth
GO:0050792 regulation of viral process
GO:0050821 protein stabilization
GO:0051702 interaction with symbiont
GO:0051817 modification of morphology or physiology of other organism involved in symbiotic interaction
GO:0051851 modification by host of symbiont morphology or physiology
GO:0060348 bone development
GO:0061077 chaperone-mediated protein folding
GO:1903900 regulation of viral life cycle
GO:1903902 positive regulation of viral life cycle
Molecular Function GO:0003755 peptidyl-prolyl cis-trans isomerase activity
GO:0005518 collagen binding
GO:0016853 isomerase activity
GO:0016859 cis-trans isomerase activity
GO:0033218 amide binding
GO:0042277 peptide binding
GO:0051082 unfolded protein binding
GO:0070063 RNA polymerase binding
Cellular Component GO:0005788 endoplasmic reticulum lumen
GO:0005790 smooth endoplasmic reticulum
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0030055 cell-substrate junction
GO:0034663 endoplasmic reticulum chaperone complex
GO:0042470 melanosome
GO:0048770 pigment granule
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1650814: Collagen biosynthesis and modifying enzymes
R-HSA-1474290: Collagen formation
R-HSA-1474244: Extracellular matrix organization
Summary
SymbolPPIB
Namepeptidylprolyl isomerase B (cyclophilin B)
Aliases CYPB; OI9; CYP-S1; HEL-S-39; SCYLP; PPIase B; S-cyclophilin; cyclophilin-like protein; epididymis secretory ......
Chromosomal Location15q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PPIB and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PPIB and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
21480325Hepatocellular CarcinomaInhibit immunity (T/NK cell function); immunotherapy targetThe TAAs consisting of cyclophilin B, squamous cell carcinoma antigen recognized by T cells (SART) 2, SART3, p53, multidrug resistance-associated protein (MRP) 3, alpha-fetoprotein (AFP) and human telomerase reverse transcriptase (hTERT) were frequently recognized by T cells and these TAA-derived peptides were capable of generating peptide-specific CTLs in HCC patients, which suggested that these TAAs are immunogenic. Cyclophilin B, SART2, SART3, p53, MRP3, AFP, and hTERT were immunogenic targets for HCC immunotherapy.
Summary
SymbolPPIB
Namepeptidylprolyl isomerase B (cyclophilin B)
Aliases CYPB; OI9; CYP-S1; HEL-S-39; SCYLP; PPIase B; S-cyclophilin; cyclophilin-like protein; epididymis secretory ......
Chromosomal Location15q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PPIB in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPPIB
Namepeptidylprolyl isomerase B (cyclophilin B)
Aliases CYPB; OI9; CYP-S1; HEL-S-39; SCYLP; PPIase B; S-cyclophilin; cyclophilin-like protein; epididymis secretory ......
Chromosomal Location15q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PPIB in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0370.914
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0870.983
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1150.971
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.010.983
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4480.847
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5880.841
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2130.637
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.430.817
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0290.989
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1770.953
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3530.941
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0170.795
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PPIB in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPPIB
Namepeptidylprolyl isomerase B (cyclophilin B)
Aliases CYPB; OI9; CYP-S1; HEL-S-39; SCYLP; PPIase B; S-cyclophilin; cyclophilin-like protein; epididymis secretory ......
Chromosomal Location15q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PPIB. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPPIB
Namepeptidylprolyl isomerase B (cyclophilin B)
Aliases CYPB; OI9; CYP-S1; HEL-S-39; SCYLP; PPIase B; S-cyclophilin; cyclophilin-like protein; epididymis secretory ......
Chromosomal Location15q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PPIB. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PPIB.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPPIB
Namepeptidylprolyl isomerase B (cyclophilin B)
Aliases CYPB; OI9; CYP-S1; HEL-S-39; SCYLP; PPIase B; S-cyclophilin; cyclophilin-like protein; epididymis secretory ......
Chromosomal Location15q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PPIB. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPPIB
Namepeptidylprolyl isomerase B (cyclophilin B)
Aliases CYPB; OI9; CYP-S1; HEL-S-39; SCYLP; PPIase B; S-cyclophilin; cyclophilin-like protein; epididymis secretory ......
Chromosomal Location15q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PPIB expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPPIB
Namepeptidylprolyl isomerase B (cyclophilin B)
Aliases CYPB; OI9; CYP-S1; HEL-S-39; SCYLP; PPIase B; S-cyclophilin; cyclophilin-like protein; epididymis secretory ......
Chromosomal Location15q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PPIB and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPPIB
Namepeptidylprolyl isomerase B (cyclophilin B)
Aliases CYPB; OI9; CYP-S1; HEL-S-39; SCYLP; PPIase B; S-cyclophilin; cyclophilin-like protein; epididymis secretory ......
Chromosomal Location15q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PPIB collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PPIB.
ID Name Drug Type Targets #Targets
DB00172L-ProlineSmall MoleculeEPRS, L3HYPDH, P3H1, P3H2, P3H3, P4HA1, P4HA2, PARS2, PPIA, PPIB, ......21
DB044471,4-DithiothreitolSmall MoleculeALDH1A1, AXIN1, CAMK2A, GSTZ1, HMGCR, LGALS1, MSRA, PPIB, TPI1, TR ......10